Fact-checked by Grok 2 weeks ago

Assay

An assay is an analytical procedure designed to measure the quantity, purity, presence, or activity of a specific substance or component within a sample, typically involving chemical, biological, or physical methods to produce a detectable signal or result. In scientific contexts, assays are fundamental tools for qualitative and , enabling precise evaluation of materials ranging from biological tissues to metal ores.

Applications in Biology and Pharmacology

In and , assays often quantify biological processes, such as enzyme activity or drug interactions, using reagents that generate signals like or for in . These can be cell-free biochemical assays, which isolate specific molecular interactions for simplicity and scalability, or cell-based assays, which incorporate living cells to better mimic physiological conditions but may introduce variability. Validation is critical, involving pre-study optimization, in-study monitoring for , and cross-validation to ensure reliability across laboratories. Historically, standardized assay guidelines emerged in the for pharmaceutical screening, evolving into comprehensive manuals that support reproducible research in .

Applications in Chemistry and Metallurgy

In chemistry, an assay determines the purity of a substance by analyzing its composition and subtracting impurities, often expressed as a percentage, which is essential for quality control in pharmaceuticals and materials science. Metallurgical assays, particularly for ores and alloys, focus on quantifying precious metals like gold or silver through techniques such as fire assay or instrumental analysis, informing mining operations and commodity valuation. These processes ensure economic viability by verifying metal content, with results influencing markets for futures trading and resource extraction.

Key Principles and Considerations

Assays must balance , specificity, and robustness, with factors like stability, experimental conditions, and statistical analysis affecting outcomes. Common types include immunoassays for detecting proteins via antibodies, enzymatic assays for metabolic pathways, and spectroscopic assays for elemental composition, each tailored to the sample and target . Advances in and have enhanced throughput, making assays indispensable in diagnostics, , and .

Introduction

Definition and Scope

An assay is a procedure designed to measure the presence, amount, or functional activity of a target entity, known as the , within a sample. These procedures can yield qualitative results indicating mere detection, quantitative outcomes providing precise measurements, or semi-quantitative assessments offering approximate levels. Assays find broad application across scientific disciplines, enabling critical analyses in diverse fields. In biochemistry, they quantify activity to elucidate metabolic pathways and protein function. In , assays evaluate efficacy by assessing interactions with biological such as receptors or enzymes. Environmental science employs assays for pollutant detection, such as bioluminescent bacterial tests to identify toxicants in water samples. In clinical diagnostics, they determine levels in patient samples to aid diagnosis and monitoring. Assays are distinguished by their underlying principles: analytical assays rely on precise chemical or physical measurements to quantify analytes directly, often using techniques like or . In contrast, bioassays measure biological responses, such as the effect of a substance on living cells, tissues, or organisms, to infer potency or activity. Over time, assays have evolved from basic qualitative tests, such as color-change indicators for simple detection, to sophisticated high-throughput automated systems capable of processing thousands of samples simultaneously for accelerated research and screening.

Etymology

The term "assay" traces its origins to the mid-14th century, deriving from the Anglo-French "assaier" and Old French "assai" or "essai," both meaning "trial," "test," or "attempt," particularly in the sense of evaluating quality or purity. This Old French root ultimately stems from the Late Latin "exagium," signifying "a weighing" or "the act of weighing," which evoked the precise examination and measurement akin to balancing scales for accuracy. Initially, the word entered English usage around 1300 in metallurgical contexts, where it described the process of testing ores and metals to determine their composition and , a practice rooted in medieval and . By the 17th century, its meaning had broadened to include general analysis, but it was not until the that "assay" fully permeated and emerging biological sciences, adapting to denote systematic quantitative evaluations of diverse substances beyond metals. A notable related term, "," emerged in the early , first recorded in , combining "bio-" (from "," meaning ) with "assay" to specify tests measuring or potency through living organisms. This evolution reflects the term's enduring adaptability from literal weighing to metaphorical and scientific scrutiny across disciplines.

Historical Overview

The origins of assays trace back to ancient civilizations, where rudimentary methods were developed to assess the purity of metals, particularly in metallurgical and alchemical practices. , one of the earliest known techniques, involved oxidizing impurities from silver or alloys by heating them in a porous cupel, allowing base metals to absorb into the material while leaving a bead of pure ; archaeological evidence indicates its use as early as 2500 BCE in regions like and . These fire-based assays formed the basis of early analytical processes, essential for trade and craftsmanship in societies. The saw the rise of colorimetric assays, which leveraged visible color changes for qualitative and of compounds. In 1887, Theodor Selivanoff devised a test using in to differentiate ketose sugars (like ) from aldose sugars (like glucose), as ketoses rapidly dehydrate to form a cherry-red condensation product. This innovation represented a shift toward more accessible biochemical detection methods, relying on chemical reactivity rather than physical separation, and influenced subsequent developments in analysis. Twentieth-century advancements revolutionized immunoassay techniques, enabling precise measurement of biomolecules at low concentrations. In the mid-1950s, Rosalyn Yalow and Solomon Berson pioneered (RIA), which uses radiolabeled antigens and specific antibodies to quantify hormones like insulin, earning Yalow the in or in 1977. Shortly thereafter, in 1971, Eva Engvall and Peter Perlmann developed the (ELISA), substituting enzymatic amplification for radioactivity to detect antigens or antibodies bound to solid surfaces, thus improving safety and scalability. From the 1980s onward, (HTS) transformed by automating the evaluation of vast compound libraries, with early implementations in pharmaceutical companies like using robotic systems to test thousands of samples daily. Post-2010, assay evolution incorporated for compact, integrated platforms that minimize sample volumes and enable real-time analysis, alongside CRISPR-based diagnostics like the 2017 SHERLOCK system, which employs Cas13 enzymes for isothermal amplification and sensitive detection. In the 2020s, assays were crucial for diagnostics through rapid antigen and molecular tests, while has advanced assay design, automation, and analysis for enhanced precision and throughput as of 2025.

General Principles

Core Steps

The core steps of an assay provide a standardized procedural framework applicable across , biochemistry, and related fields, ensuring reproducible quantification of analytes. These steps typically begin with preparation, where samples are collected, extracted to isolate the target analyte, and standardized to consistent volumes or concentrations using appropriate buffers or diluents to minimize effects and ensure compatibility with downstream processes. For instance, in biochemical assays, often involves of cells or tissues to release analytes, followed by or to remove debris, with reagent-grade chemicals used to prepare standards of known concentrations for . Following preparation, the step facilitates the specific interaction between the and detection reagents under precisely controlled conditions, such as optimal (e.g., 37°C for enzymatic reactions), , and duration to promote binding or catalytic activity while preventing non-specific reactions. This phase allows or kinetic progression, with progress curves monitored to ensure measurements occur within the linear range, typically before 10% depletion in enzymatic assays. Controlled environments, often achieved via thermostated incubators or shakers, are critical to maintain reaction and . The measurement step involves detecting the generated signal—such as , , or —using calibrated instrumentation like spectrophotometers or fluorimeters, capturing data within the instrument's linear to avoid or noise dominance. Signals are recorded as raw intensities (e.g., at a specific ), with multiple replicates performed to account for variability, ensuring the response correlates directly with concentration. In the analysis phase, raw data are processed through constructed from , applying to relate signal (S) to concentration (C), such as S = kC + b, where k is the and b . Statistical validation includes calculating the limit of detection () using the LOD = 3σ / , where σ represents the standard deviation of the blank or low-concentration replicates and is derived from the , establishing the minimum detectable level with 99% confidence. Further processing involves subtracting blanks, averaging replicates, and applying controls to quantify . Finally, reporting interprets the quantified results in context, stating analyte concentrations with error margins (e.g., ±95% confidence intervals from ) and flagging any deviations from expected ranges to support in , or applications. This step ensures , often including on conditions and instruments for .

Essential Components

Assays rely on a set of fundamental materials and to ensure reliable detection and quantification of analytes. These components include that drive the biochemical reactions, samples that provide the matrix for , controls for validation, for , and buffers with stabilizers to optimize conditions. Proper selection and handling of these elements are crucial for maintaining assay , specificity, and . Reagents form the core of most assays, enabling the interaction between the analyte and detection system. Common types include antibodies, which bind specifically to target molecules for immunoassays; enzymes, such as horseradish peroxidase or alkaline phosphatase, that catalyze reactions; and substrates like chromogenic compounds (e.g., TMB or p-nitrophenyl phosphate) that produce measurable color changes upon reaction. These reagents must be of high purity and stability, with lot-to-lot consistency verified through bridging studies to avoid variability in assay performance. Samples serve as the source material containing the of interest and can be derived from diverse matrices. Biological samples typically include , , extracts, or lysates, while non-biological samples encompass environmental matrices like or . is essential to minimize , such as through dilution or , ensuring compatibility with the assay format and preserving analyte integrity during handling. Controls are indispensable for assessing assay accuracy and reliability. Positive controls, often consisting of known concentrations of the or a , confirm the assay's ability to detect signals, while negative controls, such as blank matrices or inactive enzyme mutants, establish baseline levels. These standards enable , monitoring of signal windows (e.g., Z' factor >0.5 for robust assays), and detection of drift across runs. Instrumentation facilitates the precise execution and readout of assays, particularly in high-throughput formats. Spectrophotometers measure for colorimetric endpoints, fluorimeters detect for fluorescence-based signals, and microplates (e.g., 96- or 384-well formats in or ) support and . These tools must be calibrated for linearity and sensitivity to match the assay's . Buffers and stabilizers maintain optimal reaction environments by controlling , ionic strength, and stability. Common buffers include or Tris (25-100 mM, 7-8) with salts like NaCl (100-150 mM), while stabilizers such as BSA (0.05-1%) or prevent of enzymes and samples. These components ensure steady-state conditions, with concentrations optimized to avoid interference from assay additives like detergents.

Classification by Methodology

Based on Time and Measurements

Assays can be classified based on their temporal aspects and the frequency of , which influences their ability to capture static versus dynamic processes in analytical measurements. This classification emphasizes the timing of observations, ranging from single-point captures to continuous monitoring, allowing researchers to select methods suited to the of the reaction under study. Endpoint assays involve a single measurement taken after the reaction has proceeded for a predetermined fixed period, typically when the process is assumed to have reached completion or a steady state. In these assays, the reaction mixture is incubated under controlled conditions, and the accumulated product or signal change is quantified at the end without intermediate readings. For example, many colorimetric enzyme-linked immunosorbent assays (ELISAs) operate as endpoint methods, where substrate conversion is halted, and absorbance is read once. This approach simplifies instrumentation requirements and reduces the need for specialized equipment capable of time-series data acquisition. Kinetic assays, in contrast, involve multiple or continuous measurements over time to track the progression of the reaction, enabling the determination of rates and dynamic behaviors. These assays monitor signal changes at regular intervals or in during the reaction, often to calculate parameters like initial , defined as v = \frac{\Delta [\text{product}]}{\Delta t}, where the change in product concentration is divided by the elapsed time under initial conditions. A common application is in studies, where spectrophotometric readings track depletion or product formation over minutes to hours, providing insights into reaction mechanisms and effects. Kinetic methods require instruments like plate readers with kinetic modes but offer greater precision for reactions where linearity may not hold over extended periods. Real-time assays extend kinetic principles by providing live, continuous monitoring of the reaction as it unfolds, often integrating detection directly into the or process. These assays generate time-course data, such as curves in quantitative (qPCR), where fluorescence intensity is measured at each cycle to quantify targets exponentially. In qPCR, for instance, the cycle threshold (Ct) value is derived from the logarithmic of the , allowing or relative quantification without post-reaction . formats are particularly valuable in high-throughput settings, such as analysis, due to their and reduced hands-on time. Endpoint assays offer advantages in simplicity, lower cost, and ease of implementation, making them ideal for high-volume screening where only final outcomes matter, though they risk inaccuracies if reactions deviate from or complete unexpectedly. Kinetic and assays provide superior dynamic insights, such as detecting non-linear phases or transient intermediates, which are crucial for mechanistic studies or validating reaction conditions, but they demand more sophisticated equipment and data analysis, potentially increasing complexity and expense. The choice depends on the assay's goal: for straightforward quantification versus kinetic or for .

Based on Analyte Detection

Assays based on detection are classified according to the number of targets they can analyze simultaneously, which directly impacts their throughput and applicability in and diagnostics. Single-analyte assays, also referred to as singleplex assays, target and quantify one specific or substance per test, offering high and reduced risk of from non-target components. These assays rely on highly specific recognition elements, such as or antibodies, to generate a measurable signal proportional to the analyte's concentration. For instance, the assay, commonly used in devices, employs the glucose oxidase to selectively oxidize glucose in samples, producing that is detected colorimetrically or electrochemically for accurate quantification. This approach ensures reliable results in clinical settings, with detection limits often reaching micromolar levels, making it a cornerstone for managing . In contrast, multi-analyte assays, or multiplex assays, enable the parallel detection of multiple analytes in a single sample, conserving precious biological material and accelerating . These assays utilize platforms like bead-based arrays, where spectrally distinct microspheres capture different targets via immobilized antibodies, allowing simultaneous readout through or imaging. A widely adopted example is the Luminex multiplex bead array system, which can profile over 100 —such as and tumor necrosis factors—in or lysates from a minimal volume, typically 25-50 microliters, with sensitivities comparable to enzyme-linked immunosorbent assays (ELISAs) for individual analytes. This technology has revolutionized profiling in , enabling comprehensive mapping in studies of and infectious diseases. High-content screening (HCS) extends multi-analyte detection into the realm of cellular phenotyping, using automated to capture and analyze multiparametric images of cells or tissues. In HCS, fluorescent probes label multiple cellular components—such as nuclei, cytoskeletal elements, and organelles—allowing quantitative assessment of dozens of features like cell count, , translocation events, and intensity distributions in thousands of cells per well. For example, HCS platforms have been instrumental in , screening compound libraries for effects on nuclear factor-kappa B () signaling in live cells by tracking its nuclear translocation alongside viability markers. This method generates multidimensional datasets that reveal subtle phenotypic changes unattainable with traditional assays, though it requires sophisticated image analysis software for feature extraction and statistical validation. Multiplexing in both multi-analyte and high-content formats introduces challenges, particularly among detection reagents, where or probes intended for one target bind unintended analytes, leading to signal overlap and reduced specificity. This issue is exacerbated in bead arrays, where spatial separation is limited, potentially leading to elevated measurements in complex matrices like . Additionally, the data complexity from high-dimensional outputs demands robust bioinformatics pipelines to handle noise, variability, and correlations, often employing to deconvolute signals and ensure across batches. Strategies to mitigate these include rigorous validation and matrix-matched controls, which have improved assay performance in clinical studies.

Based on Result Format

Assays are classified based on the format of their results, which determines how the output data is interpreted and applied in . This classification emphasizes the of the output—whether it provides definitive categories, measurable values, or intermediate gradations—allowing researchers to select methods suited to the required precision and downstream applications. The primary categories include qualitative, semi-quantitative, and quantitative assays, each differing in the and type of information yielded from the process. Qualitative assays produce binary or categorical results, indicating the presence, absence, or type of an without specifying amounts. These assays are valuable for rapid screening in diagnostics and research, where confirmatory detection suffices. For instance, agglutination tests in detect antibody-antigen interactions through visible clumping, yielding a simple positive or negative outcome based on observable aggregation. Similarly, colorimetric assays like the nitroblue tetrazolium test for bacterial activity result in a color change signaling enzymatic presence. Such methods rely on threshold-based interpretations during the readout phase of assay execution. Quantitative assays deliver numerical values that quantify the analyte's concentration or activity, enabling precise comparisons and statistical analysis. These are essential in fields like and , where exact measurements inform dosing or compliance. A common approach involves constructing a standard curve from known analyte concentrations plotted against instrument signals, from which unknown samples are interpolated. The concentration is calculated as [analyte] = \frac{signal - blank}{slope}, where the slope derives from the line, providing a direct measure of analyte levels. Enzyme-linked immunosorbent assays () exemplify this, outputting absorbance values convertible to concentrations via . Semi-quantitative assays offer graded scales that bridge qualitative simplicity and quantitative detail, estimating levels through ordinal categories rather than exact numbers. These are practical for resource-limited settings, providing relative abundance without full . In immunoassays, results are often reported as trace, +, ++, +++, or ++++ based on signal intensity, correlating to low, moderate, high, or very high analyte presence. Lateral flow assays, such as pregnancy tests, use line intensities for semi-quantitative hormone detection, where stronger bands indicate higher concentrations within predefined ranges. This format facilitates quick while approximating quantification. Additionally, assays differ in data output types: analog results provide continuous signals, such as varying voltage or from sensors, which must be digitized for ; in contrast, digital outputs yield values directly, like codes from scanners or count-based results from . Analog formats, common in traditional , capture nuanced gradients but require conversion, whereas ones, prevalent in modern automated systems, enhance and with computational tools. This distinction influences assay design for compatibility with analytical software.

Based on Sample Handling

Assays are classified based on sample handling according to the physical state of the sample and the techniques used to prepare it for analysis, ensuring compatibility with downstream detection methods. This classification addresses the diverse origins of samples in biological, environmental, and chemical contexts, where proper handling minimizes degradation, contamination, or loss of analytes. Liquid samples, such as serum, plasma, urine, or saliva, are among the most common in biochemical and clinical assays due to their homogeneity and ease of manipulation. These samples often require minimal initial processing but may undergo dilution to adjust concentrations within the assay's dynamic range or to reduce matrix effects that could interfere with detection. For instance, in liquid chromatography-mass spectrometry (LC-MS) bioanalysis, dilution is routinely applied to bring analyte levels into the validated range, enhancing accuracy and precision. Solid samples, like tissues or biopsies, necessitate homogenization to disrupt cellular structures and release intracellular contents for analysis. Tissue homogenization typically involves mechanical disruption using bead beating or ultrasonic methods, followed by extraction to isolate analytes from the matrix; this is critical in proteomics assays where incomplete lysis can lead to biased results. Gaseous samples, such as air pollutants including volatile organic compounds (VOCs), are handled through collection via adsorption tubes or impingers, converting them into a liquid or solid phase for subsequent assaying, as seen in gas chromatography-mass spectrometry (GC-MS) for environmental monitoring. Key preparation methods focus on rendering samples amenable to assay conditions. Lysis breaks open cells or tissues to liberate analytes, often using chemical agents like detergents or enzymatic treatments, and is a foundational step in nucleic acid or protein assays. Extraction techniques, such as solid-phase extraction (SPE), enable cleanup by binding analytes to a stationary phase while removing interferents, improving sensitivity in clinical top-down proteomics. Dilution, as noted, standardizes sample volume and concentration, particularly in immunoassays or toxicology testing where "dilute-and-shoot" approaches simplify workflows without extensive preprocessing. Assays further differ by whether they are conducted in vivo or , influencing sample sourcing and handling. assays use isolated systems, such as cell cultures in petri dishes, where samples are prepared externally through controlled or dilution to mimic physiological conditions without whole-organism variability. In contrast, assays involve whole-organism exposure, with samples collected directly from living subjects (e.g., blood or tissue from animal models), requiring ethical considerations and post-exposure extraction to capture systemic responses. This distinction ensures assays reflect either simplified mechanistic insights or holistic biological effects. Automation in sample handling, particularly via microfluidic chips, reduces manual intervention and sample volume while enhancing reproducibility. These systems integrate , , and dilution in a single device, using electro-pneumatic controls for precise metering; for example, a handheld microfluidic platform has demonstrated automated immunoassays for detection with limits comparable to traditional ELISAs, using minimal volumes. Such technologies are pivotal for point-of-care applications, minimizing handling errors in resource-limited settings.

Based on Signal Strategies

Signal strategies in assays encompass the approaches used to generate, enhance, or detect signals arising from analyte-probe interactions, playing a pivotal role in determining the of the . These strategies are essential for overcoming challenges posed by low concentrations in complex samples, enabling reliable quantification across diverse applications such as diagnostics and research. By tailoring signal generation to the assay's requirements, researchers can balance simplicity, speed, and detection limits without relying on external hardware specifics. Direct detection methods rely on the inherent signal produced by the event itself, without additional steps, offering straightforward implementation for high-abundance targets. In fluorescence-based direct assays, for instance, a attached to the or emits light upon only when bound, allowing measurement of through changes in intensity, , or lifetime; this approach is exemplified in polarization assays where rotational mobility decreases upon complex formation, providing a simple readout proportional to bound fraction. Such techniques are valued for their rapidity and minimal sample manipulation but are generally limited to analytes present at micromolar concentrations or higher due to the single-signal-per-binding event. To achieve greater sensitivity, signal amplification strategies multiply the detectable output per analyte molecule, with enzymatic methods being among the most established. Enzymatic amplification employs catalysts like (HRP) conjugated to probes, which trigger cascading reactions producing numerous detectable products; in the (ELISA), HRP oxidizes substrates such as tetramethylbenzidine to generate a colorimetric signal, where each can yield thousands of chromophores per minute, extending detection limits to picomolar levels. Nucleic acid-based amplification further boosts signals through iterative replication, as in immuno-PCR, where antibody-DNA conjugates link immunorecognition to (PCR) cycles that exponentially amplify detectable DNA tags, achieving femtomolar sensitivity by combining immunological specificity with exponential growth. These methods, pioneered in the 1970s for ELISA and 1980s for PCR, have become foundational for ultrasensitive bioassays. Label-free signal strategies detect binding-induced physical perturbations without introducing reporter molecules, preserving native analyte behavior and simplifying workflows. Surface plasmon resonance (SPR) exemplifies this by monitoring refractive index changes near a sensor surface upon analyte binding, which shifts the plasmon resonance angle in real-time, enabling direct observation of association and dissociation kinetics with affinities in the nanomolar range. This technique, first demonstrated for biosensing in the early , avoids labeling artifacts and supports kinetic analysis, though it requires careful surface chemistry for optimal signal-to-noise. For low-abundance analytes, avidity-enhancing strategies leverage multi-valent interactions to amplify effective binding strength; by designing probes or surfaces with multiple binding sites, such as bispecific antibodies or clustered ligands, the cumulative avidity effect increases residence time and detection probability, allowing sub-picomolar sensitivity for rare targets like cytokines in . These approaches exploit cooperative binding thermodynamics, where individual low-affinity interactions (millimolar Kd) yield high-avidity complexes (picomolar effective Kd), as quantified in biophysical studies of multivalent systems.

Based on Detection Techniques

Assays rely on various detection techniques to transduce the presence or concentration of an into a measurable signal, with playing a central role in achieving , specificity, and throughput. These methods encompass optical, electrochemical, mass-based, and emerging digital approaches, each suited to different analyte types and experimental demands. Optical techniques dominate due to their non-invasive nature and compatibility with microscale formats, while electrochemical methods offer portability for point-of-care applications. Mass-based detection provides high-resolution identification, and digital assays enable precise absolute quantification without standards.

Optical Detection

Optical detection techniques measure light interactions with analytes or labels to generate quantifiable signals, often using spectrophotometers, fluorimeters, or plate readers as key . Absorbance-based methods quantify the reduction in transmission through a sample, governed by the Beer-Lambert law, which states that A is proportional to the concentration c, path length l, and molar absorptivity \epsilon:
A = \epsilon l c
This principle underpins colorimetric assays, where chromogenic substrates produce colored products whose intensity correlates with analyte levels, enabling detection limits in the micromolar range for routine biochemical analyses.
Fluorescence detection involves exciting fluorophores with light of a specific and measuring emitted light at a longer , providing high sensitivity due to low and single-molecule detection capabilities. Instrumentation such as confocal microscopes or cytometers facilitates , as seen in resonance energy transfer () assays for real-time , with quantum yields often exceeding 0.5 for optimized dyes. detection, including and , relies on light emission from chemical reactions without external excitation, reducing autofluorescence interference; for instance, enzyme-linked assays using substrates achieve attomolar sensitivity in high-throughput formats like 96-well plates.

Electrochemical Detection

Electrochemical detection converts analyte-induced reactions into electrical signals, with being a prominent technique where current is measured at a fixed potential to quantify involved in . In bioassays, s coated with biorecognition elements, such as enzymes or antibodies, generate currents proportional to analyte concentration; for example, glucose oxidase-based sensors produce , which is oxidized at the to yield microampere-level signals detectable by portable potentiostats. This method excels in monitoring, with linear ranges spanning 1 nM to 1 and response times under 10 seconds, making it ideal for implantable or wearable devices.

Mass-Based Detection

Mass-based detection identifies analytes by their or binding-induced mass changes, leveraging instruments like or quartz crystal microbalances for precise molecular characterization. Advanced iterations integrate microcantilevers to measure binding mass shifts in picograms, offering label-free detection with resolutions down to 0.1% mass change. (), particularly liquid chromatography-tandem (LC-/), provides unparalleled specificity by fragmenting ions and matching spectra to databases, enabling simultaneous quantification of hundreds of proteins in complex matrices with limits of detection in the femtogram range per microliter. These techniques are instrumental in , where enhances accuracy to within 5-10% relative standard deviation.

Emerging Detection Techniques

Digital assays partition samples into thousands of isolated reactions for statistical counting of positive events, bypassing calibration curves for absolute quantification. Droplet digital (ddPCR) exemplifies this, emulsifying templates into 20,000-40,000 nanoliter droplets, amplifying them via , and detecting fluorescence-positive droplets to yield copy numbers per microliter with Poisson-distributed precision, achieving <5% variability for inputs as low as 1 copy/μL. Instrumentation like droplet generators and readers supports high-throughput processing of up to 2 million reactions per run, revolutionizing quantification in low-abundance scenarios such as rare mutation detection.

Classification by Target

Molecular Targets

Assays targeting molecular biomolecules, such as DNA, RNA, and proteins, enable the detection, quantification, and analysis of genetic and proteomic information at the molecular level. These techniques are fundamental in molecular biology for studying gene expression, mutations, and protein interactions, often involving amplification, hybridization, or immunological detection methods. DNA assays primarily focus on amplification, sequencing, and hybridization to identify specific sequences or structural variations. Polymerase chain reaction (PCR), developed in the 1980s, amplifies targeted DNA segments through repeated cycles of denaturation, annealing, and extension using a thermostable DNA polymerase, allowing detection from minute sample quantities. Sanger sequencing, introduced in 1977, determines nucleotide order by incorporating chain-terminating dideoxynucleotides during DNA synthesis, producing fragments separable by electrophoresis for sequence readout. Hybridization-based assays, exemplified by the Southern blot developed in 1975, involve digesting DNA, separating fragments via gel electrophoresis, transferring to a membrane, and probing with labeled complementary nucleic acids to detect specific genes or rearrangements. RNA assays adapt DNA techniques to study transcriptomes, emphasizing reverse transcription to convert RNA to complementary DNA (cDNA) for subsequent analysis. Reverse transcription PCR (RT-PCR) combines reverse transcriptase to synthesize cDNA from RNA templates with PCR amplification, enabling sensitive detection of gene expression levels from low-abundance transcripts. Microarrays for expression profiling, pioneered in 1995, immobilize thousands of DNA probes on a solid surface to hybridize with fluorescently labeled cDNA derived from RNA samples, allowing simultaneous quantification of multiple gene transcripts through signal intensity measurement. Protein assays rely on separation, immunological recognition, or mass-based identification to assess abundance, modifications, or interactions. Western blotting, established in 1979, separates proteins by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (), transfers them to a membrane, and detects specific targets using antibodies conjugated to enzymes or fluorophores for visualization. Immunoassays like the sandwich enzyme-linked immunosorbent assay () capture proteins between two antibodies—one immobilized and one detection-linked—amplifying signals enzymatically; this format is widely used for quantifying cytokines such as interleukins in biological fluids. Post-2000 advancements have expanded functional and high-throughput molecular assays. CRISPR-Cas9 systems, demonstrated in 2012, utilize guide RNA to direct the Cas9 endonuclease for precise DNA cleavage, enabling functional assays of gene knockout or editing effects in vitro and in cells. In proteomics, mass spectrometry-based assays, refined through multidimensional approaches since the early 2000s, ionize peptides from digested proteins and analyze mass-to-charge ratios to identify and quantify thousands of proteins simultaneously, providing insights into proteome dynamics.

Cellular and Tissue Targets

Assays targeting cellular and tissue levels evaluate holistic responses such as viability, proliferation, cytotoxicity, and functional signaling, providing insights into overall cellular health and tissue-like behaviors without isolating individual molecules. These methods are essential in biomedical research for screening compounds, studying disease mechanisms, and developing therapeutics, often using intact cells or engineered tissue models to mimic physiological conditions. Viability and proliferation assays assess the metabolic activity and membrane integrity of cells to quantify live cell populations. The , a colorimetric method, relies on the reduction of tetrazolium dye (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) by viable cells' dehydrogenases to insoluble purple formazan crystals, which are solubilized and measured spectrophotometrically at 570 nm to estimate cell number or metabolic activity. Introduced in 1983, it is widely used for high-throughput screening of cell proliferation and cytotoxicity in 96-well plates, with absorbance proportional to viable cell count. In contrast, the distinguishes live from dead cells based on membrane permeability; viable cells with intact membranes exclude the blue dye, appearing clear under a microscope, while dead cells take up the dye and stain blue, allowing manual counting via hemocytometer for rapid viability assessment typically exceeding 90% accuracy in fresh suspensions. Cytotoxicity assays detect cell damage by measuring the release of intracellular contents into the culture medium. The release assay quantifies LDH enzyme leakage from compromised plasma membranes, where released LDH catalyzes the conversion of lactate to pyruvate, reducing a tetrazolium salt to a colored formazan product detectable at 490-500 nm; this non-radioactive method correlates LDH levels with cell lysis percentage, offering sensitivity for detecting as low as 5-10% cytotoxicity in mammalian cell lines. Developed as a simple alternative to , it is applied in 96-well formats for evaluating toxin-induced damage over 24-72 hours. Functional assays probe dynamic cellular processes like signaling and population heterogeneity. Calcium imaging monitors intracellular calcium ion fluctuations as indicators of signaling pathways, using fluorescent dyes such as that exhibit wavelength shifts upon Ca²⁺ binding, enabling ratiometric measurements via dual-excitation fluorescence microscopy to track transient elevations (e.g., 100 nM to 1 μM) in response to stimuli like neurotransmitters. This technique, advanced by improved indicators in 1985, visualizes spatial and temporal dynamics in live cells with sub-second resolution. Flow cytometry for cell sorting analyzes and isolates cells based on light scatter and fluorescence properties; cells in suspension are hydrodynamically focused into a stream, interrogated by lasers, and sorted via electrostatic deflection of droplets containing target cells labeled with fluorophore-conjugated antibodies, achieving purities over 95% for subpopulations like immune cells. Commercialized since the 1970s, it processes up to 10,000 cells per second for functional studies such as apoptosis detection. Advanced tissue-level assays emulate organ physiology using microfluidic platforms. Organ-on-chip systems integrate human cells into compartmentalized chips with fluidic channels and mechanical cues to replicate tissue microenvironments, such as alveolar barriers in lung-on-chip models where epithelial and endothelial cells form functional interfaces responsive to airflow and immune challenges. Emerging post-2010, these devices model complex responses like inflammation or drug permeability with higher physiological relevance than 2D cultures, reducing animal testing needs.

Environmental and Chemical Targets

Assays for environmental and chemical targets focus on detecting and quantifying abiotic substances in non-biological matrices such as water, soil, air, and food products, aiding in pollution monitoring, regulatory compliance, and safety assessments. These methods prioritize sensitivity, specificity, and rapidity to address contaminants that pose risks to ecosystems and human health without involving living cellular systems. Common techniques leverage immunological, electrochemical, colorimetric, chromatographic, and bioluminescent principles to identify trace levels of pollutants. For contaminants, enzyme-linked immunosorbent assays (ELISA) are widely employed to detect pesticide residues in environmental samples like groundwater and soil. ELISA operates by immobilizing antibodies specific to the pesticide on a solid surface, where the sample antigen competes with a labeled conjugate for binding sites, producing a colorimetric signal proportional to concentration that can be measured spectrophotometrically. This method achieves detection limits as low as 0.01 μg/L for pesticides such as and , making it suitable for field screening in resource-limited settings. Biosensors for heavy metals, such as lead and , utilize biological recognition elements like enzymes or DNA coupled with transducers to generate electrochemical or optical signals upon metal binding. These devices offer portability and real-time detection in wastewater, with sensitivities reaching parts-per-billion levels through nanomaterials enhancing signal amplification. The methylene blue active substances (MBAS) method serves as a standard colorimetric assay for anionic surfactants in water samples, exploiting the ion-pair formation between the surfactant and methylene blue dye. In this procedure, the sample is acidified and extracted with chloroform, where the blue complex partitions into the organic phase and is quantified by absorbance at 650 nm, providing results in as little as 30 minutes with a detection limit of 0.02 mg/L sodium dodecyl sulfate equivalents. This technique is integral to wastewater treatment monitoring and has been standardized for compliance with environmental regulations. In petrochemistry, gas chromatography (GC) assays are essential for analyzing hydrocarbons in contaminated environmental media, separating volatile and semi-volatile compounds based on their interaction with a stationary phase. Coupled with flame ionization or mass spectrometry detectors, GC quantifies petroleum hydrocarbons like benzene and polycyclic aromatic hydrocarbons (PAHs) in soil and water extracts, achieving resolution of individual congeners at low microgram-per-kilogram levels to assess remediation progress. These methods support site characterization under frameworks like the U.S. EPA's Superfund program. For food safety, ATP bioluminescence assays provide a rapid indicator of microbial contamination on surfaces and in processing environments by measuring adenosine triphosphate (ATP) as a proxy for viable cell counts. The assay involves swabbing a sample, lysing cells to release ATP, and reacting it with luciferase and luciferin to produce light quantified in relative light units, correlating to microbial loads above 10^3 CFU/cm² within 15 seconds. This non-specific yet high-throughput approach is validated for hygiene verification in food production lines.

Pharmaceutical and Clinical Targets

In pharmaceutical and clinical contexts, assays target drugs, pathogens, and biomarkers to support drug development, therapeutic monitoring, and disease diagnosis. These assays enable the quantification of drug concentrations in biological matrices for pharmacokinetic (PK) studies and the assessment of biological potency through standardized bioassays. In virology, they measure infectious viral particles and nucleic acid loads to guide antiviral therapies. Clinical applications focus on detecting biomarkers in blood or secretions to inform prognosis and treatment, with emerging high-resolution techniques like single-cell RNA sequencing () advancing personalized medicine. Protein immunoassays, such as enzyme-linked immunosorbent assays (), are often integrated for initial biomarker detection in these workflows. Drug assays are essential for evaluating pharmacokinetics, which describe drug absorption, distribution, metabolism, and excretion. High-performance liquid chromatography (HPLC), frequently coupled with tandem mass spectrometry (), serves as a gold-standard method for quantifying drug levels in plasma or serum with high sensitivity and specificity, allowing detection limits as low as nanograms per milliliter. This technique supports PK screening in early drug development by providing rapid, reproducible data on drug exposure across species. For potency assessment, bioassays measure biological activity, such as the median lethal dose (), which quantifies the dose causing 50% mortality in animal models and remains a benchmark in toxicology despite ethical concerns over animal use. The , originally developed in 1927 for standardizing toxin potency, informs hazard classification for pharmaceuticals, with values below 50 mg/kg indicating high acute toxicity. In virology, plaque assays determine viral titer by infecting cell monolayers and counting plaques—clear zones of cell death—formed by viral replication, yielding results in plaque-forming units (PFU) per milliliter. This method, validated for viruses like , provides a direct measure of infectious particles and is crucial for vaccine potency testing, with titers typically ranging from 10^5 to 10^8 PFU/mL in clinical isolates. Complementary quantitative reverse transcription polymerase chain reaction (qRT-PCR) assays quantify viral load by amplifying and detecting viral RNA in real-time, offering sensitivity down to 10-100 copies per reaction and enabling monitoring of treatment efficacy in infections like or . In clinical practice, qRT-PCR cycle threshold (Ct) values inversely correlate with viral load, where Ct < 25 often indicates high infectivity. Clinical biomarker assays detect molecules indicative of disease states, such as cardiac troponin I or T, which are released from damaged cardiomyocytes and serve as primary markers for acute myocardial infarction. High-sensitivity troponin assays, approved by regulatory bodies like the since 2017, detect elevations as low as 1-5 ng/L within hours of injury, improving early diagnosis and risk stratification with prognostic value for long-term cardiovascular events. Cytokine profiling in bodily secretions, such as saliva or bronchoalveolar lavage fluid, uses multiplex bead-based assays like to simultaneously measure multiple cytokines (e.g., IL-6, TNF-α) at picogram levels, revealing inflammatory patterns in conditions like COVID-19 or autoimmune diseases. These profiles correlate with disease severity, where elevated IL-6 levels (>100 pg/mL) predict poor outcomes in respiratory infections. Recent advances post-2015 include single-cell sequencing (scRNA-seq) for , which profiles transcriptomes from individual patient cells to identify heterogeneous responses to therapies. In , scRNA-seq reveals dynamics, enabling tailored immunotherapies by pinpointing drug-resistant subpopulations, as demonstrated in studies of where it identified rare therapy-responsive clones. This technology, with throughputs exceeding 10,000 cells per sample, supports precision dosing and combination regimens.

Quality and Standards

Validation Criteria

Validation criteria for assays encompass standardized parameters and guidelines that ensure the reliability, , and of methods across various applications, including bioanalytical, diagnostic, environmental, chemical, and metallurgical testing. These criteria are essential to minimize variability, confirm method performance, and support regulatory submissions or clinical . Key parameters focus on quantitative metrics that evaluate how well an assay performs under controlled conditions, while regulatory frameworks provide overarching standards for implementation. In non-biological contexts, such as metallurgical assays, standards like ASTM E1806 specify procedures for in determining metal content. Accuracy refers to the closeness of measured values to the true or nominal concentration of the , typically assessed using samples across multiple validation runs. In bioanalytical assays, acceptance criteria often require accuracy within ±15% of nominal values for standards, with allowances up to ±20% at the lower limit of quantitation (LLOQ). measures the reproducibility of results, expressed as (CV), and is evaluated through intra- and inter-run variability; for chromatographic methods, it is generally limited to ±15% CV, expanding to ±20% at the LLOQ. Specificity, or selectivity, ensures the assay distinguishes the target from potential interferences, such as components or metabolites, verified by analyzing blank samples from multiple sources without significant interference signals. determines the lowest detectable concentration with acceptable accuracy and , often defined by the LLOQ where the signal is at least five times the blank response. For diagnostic assays, are particularly critical, representing the true positive rate (proportion of diseased subjects correctly identified) and true negative rate (proportion of non-diseased subjects correctly identified), respectively. These parameters are independent of disease but are visualized and optimized using (ROC) curves, which plot against 1-specificity across various thresholds; the area under the curve () quantifies overall performance, with values closer to 1 indicating superior discriminatory ability. Overall accuracy in this context is the proportion of correct classifications, though it can be influenced by . Regulatory guidelines enforce these parameters for clinical and pharmaceutical assays. The U.S. (FDA) requires full validation of bioanalytical methods per the ICH M10 guideline (adopted June 2024), including documentation of accuracy, , specificity, and sensitivity for pivotal submissions like new drug applications. Similarly, the () mandates validation per ICH M10 guidelines (effective 2023), emphasizing selectivity, sensitivity (via LLOQ), accuracy (±15% deviation), and (≤15% ) for methods measuring drug concentrations in biological matrices. ICH M10, effective from 2023 and adopted by the FDA in June 2024, harmonizes these requirements globally. Additionally, the FDA issued a specific guidance on Bioanalytical Method Validation for Biomarkers in early 2025, adapting criteria for non-drug analytes like biomarkers. (GLP), outlined in 21 CFR Part 58 and principles, applies to nonclinical studies supporting regulatory decisions, requiring standardized procedures, equipment calibration, personnel training, and to uphold in assay validation. The :2022 standard for medical laboratories updates validation requirements to include risk-based approaches for method , emphasizing ongoing monitoring of and accuracy to ensure competence in diagnostic testing. Statistical tools like Bland-Altman plots facilitate method comparisons by graphing the difference between two assays against their mean, identifying (mean difference) and limits of agreement (±1.96 standard deviations), which aids in assessing interchangeability without assuming .

Common Challenges and Solutions

One prevalent challenge in assay development and execution is effects, where co-extracted endogenous components from biological samples interfere with detection, leading to suppression or enhancement in techniques like liquid chromatography-mass spectrometry (LC-MS/MS). This interference compromises accuracy and reproducibility, particularly in complex matrices such as or extracts. Low poses another issue, especially in bioassays targeting low-abundance analytes, where or insufficient signal amplification limits detection thresholds, hindering early-stage identification. Variability across replicates or batches further exacerbates these problems, often stemming from inconsistent quality, environmental factors, or operator handling, which can inflate error rates in . To mitigate matrix effects, internal standards—such as stable isotope-labeled analogs—are widely employed to normalize responses and correct for suppression, ensuring quantitative reliability in LC-MS/MS workflows. In immunoassays, blocking agents like (BSA) or non-fat dry milk are routinely added to saturate non-specific binding sites on surfaces, reducing interference and improving signal-to-noise ratios. For addressing low sensitivity, strategies include signal amplification via enzymatic cascades or conjugates, which enhance detection limits by orders of magnitude without altering assay specificity. Variability is effectively reduced through , such as robotic handling systems, which standardize pipetting and incubation steps, achieving cell seeding consistency within 5-6% standard deviation in microchannel assays. Emerging post-2020 applications leverage (AI) for outlier detection in high-throughput assay data, employing ensemble methods like multi-round resampling and testing to identify in datasets, thereby enhancing data quality and reducing false positives. These AI tools integrate with image-based phenotypic to automate anomaly flagging, improving in complex screens. A notable in troubleshooting involves a 14-plex multiplex sandwich (MSA) using commercial ELISA-optimized for like ANG2, EGFR, and LEP. Experiments revealed significant exceeding analyte signals for CEA and affecting over 50% of when mixing detection antibodies, primarily due to non-specific interactions scaling as 4N(N-1) with the number of analytes (N). through antibody microarrays eliminated this issue, enabling scalable 50-plex analysis without optimization delays.

Resources and Databases

Bioactivity and Data Repositories

, hosted by the (NCBI) under the (NIH), serves as a key repository for data in and . It encompasses over 2.5 million experiments, including results from small-molecule and RNAi screens, along with detailed annotations on assay protocols, , and outcomes. This NIH-funded resource, actively updated as of November 2025, enables researchers to query and analyze bioactivity profiles for millions of compounds, facilitating the identification of potential therapeutic leads. In 2025, further integrated AlphaFold3 structures to predict bioactivities for over 200 million protein-ligand pairs, expanding coverage for understudied . ChEMBL, developed and maintained by the (EMBL-EBI), provides a manually curated collection of bioactivity data extracted from and deposited datasets, emphasizing drug-like molecules. As of release 37 in 2025, it includes approximately 3.1 million distinct compounds tested against 18,500 targets, with over 22 million bioactivity measurements covering binding affinities, functional potencies, and ADMET properties. This open-access platform supports cheminformatics analyses and by integrating chemical structures, genomic data, and standardized activity values, making it indispensable for target validation in pharmaceutical research. BindingDB focuses specifically on protein-small molecule interactions, curating experimentally measured binding affinities such as , Kd, and values from peer-reviewed publications. As of November 2025, it holds approximately 3.5 million binding data points for over 1.6 million drug-like compounds across 12,000 protein targets, including imports from sources like to enhance coverage. Designed as a FAIR-compliant knowledgebase, it aids in structure-activity relationship studies and optimization for . Since 2021, these repositories have begun incorporating AI-driven predictions to address limitations in experimental data, particularly through integrations of -generated protein structures for inferring untested bioactivities. For instance, models have been used to predict ligand binding potencies, augmenting datasets in and by filling gaps in structural coverage for novel targets. Such enhancements enable more comprehensive virtual assays without relying solely on wet-lab results.

Protocol and Method Collections

Protocols.io serves as an open-source, collaborative platform dedicated to the development, sharing, and refinement of step-by-step scientific protocols, including those for assays, enabling researchers to create version-controlled methods that enhance across disciplines. Launched in 2014 by founders Lenny Teytelman, Irina Makkaveeva, and Alexei Stoliartchouk, it initially focused on wet-lab recipes and later expanded to support computational protocols and broader research workflows. In 2023, acquired the platform to drive further open research initiatives, integrating it with existing resources like Protocol Exchange to host over 25,000 public protocols and facilitate their migration for wider accessibility. This expansion has grown the repository's user base exponentially, with features for institutional subscriptions and global support teams to promote standardized dissemination. The Assay Guidance Manual, hosted by the National Center for Advancing Translational Sciences (NCATS) on the NCBI Bookshelf, provides detailed, evidence-based guides for best practices in assay design, optimization, and validation, particularly for (HTS) and lead optimization in . Developed collaboratively by over 100 international experts and updated quarterly since its inception, the manual covers assay formats, selection, statistical validation, artifacts, and adaptations for automation, serving as a critical resource for ensuring robust, reproducible screening protocols. It emphasizes quantitative biology and pharmacology principles to minimize false positives and support probe development, with chapters on secondary assays and data standards freely available under a . The Minimum Information about a Experiment (MIAPE) guidelines, established by the Human Proteome Organization's Standards Initiative (HUPO-PSI), outline the essential metadata required for reporting experiments, with a focus on assays involving , , and molecular interactions to promote data and . First articulated in through MIAPE principles and modular documents like MIAPE-MS and MIAPE-Quant, these guidelines specify minimum reporting standards for experimental context, instrumentation, and quantification methods, registered under the MIBBI project for cross-domain alignment. Primarily -oriented, MIAPE ensures comprehensive documentation of assay parameters, such as and , to facilitate deposition in public repositories and . Post-2022 developments in protocol collections have increasingly incorporated artificial intelligence to optimize assay methods, with platforms like Protocols.io introducing AI-powered tools for protocol design, troubleshooting, and workflow refinement to accelerate reproducibility and experimental efficiency. These integrations, aligned with broader advancements in AI for scientific method automation, build on repository expansions to support dynamic, data-driven protocol evolution without altering core standardization frameworks.

References

  1. [1]
    Preface - Assay Guidance Manual - NCBI Bookshelf - NIH
    May 1, 2012 · An assay is an analytical measurement procedure defined by a set of reagents that produces a detectable signal, allowing a biological process to ...
  2. [2]
    What Is an Assay and How Investors Think About It? - Investopedia
    An assay is a testing method to analyze a substance's composition and quality, especially in metals and ores, to determine its ingredients.What Is an Assay? · Metals Testing · Metals Futures Market
  3. [3]
    ASSAY MEANS PURITY, RIGHT? - Merck Group
    Assay means to examine a chemical to determine its purity, usually expressed as a percent, calculated by subtracting impurities from 100.
  4. [4]
    Definition of assay - NCI Dictionary of Cancer Terms
    Listen to pronunciation. (A-say) A laboratory test to find and measure the amount of a specific substance.<|control11|><|separator|>
  5. [5]
    Assay Process: What It Is & Why It Matters - Ledoux & Co.
    Dec 29, 2024 · An assay is a comprehensive analytical procedure used to determine the presence and quantity of a specific substance within a material sample.
  6. [6]
    What Assays are used for Drug Discovery & Development? - Enzo
    Jan 27, 2023 · An assay is an analytical measurement procedure defined by a set of reagents that produces a detectable signal for quantifying a biological process.
  7. [7]
  8. [8]
    Assay Development in Drug Discovery | Danaher Life Sciences
    Assays are procedures that assess the effectiveness of the chosen drug candidate on the desired target, which can be molecular or biochemical targets. It can ...
  9. [9]
    Methods to Measure Waterborne Contaminants Research to ...
    Dec 20, 2024 · Microtox assay, The Microtox assay is a rapid screening assay for water samples that uses bioluminescent bacteria to detect toxicants in water.
  10. [10]
    Biomarker Assays - Creative Diagnostics
    Biomarker assays play a crucial role in detecting and quantifying these indicators, providing valuable information about an individual's health status.
  11. [11]
    Difference Between Bioassay and Chemical Assay
    Aug 12, 2020 · Bioassay is a method that determines the concentration or potency of a substance by its effect on living cells or tissues while chemical assay is a set of ...<|control11|><|separator|>
  12. [12]
    Bioassay - an overview | ScienceDirect Topics
    A biological assay, or bioassay, is an analytical method used to measure the functional activity of a molecule on living organisms, tissue, or live cells.<|control11|><|separator|>
  13. [13]
    Assay: Types, Techniques, Significance, Applications etc
    Sep 23, 2023 · Applications: Assays are employed in diverse fields such as biology, chemistry, medicine, pharmacology, and environmental science. Biochemical ...
  14. [14]
    Origin and evolution of high throughput screening - PMC
    This article reviews the origin and evolution of high throughput screening (HTS) through the experience of an individual pharmaceutical company.Missing: qualitative | Show results with:qualitative
  15. [15]
    Assay - Etymology, Origin & Meaning
    Originating c. 1300 from Anglo-French assaier and Old French assai, assaying means to test or try, especially to assess quality or purity.
  16. [16]
    exagium - Wiktionary, the free dictionary
    Latin. Etymology. From exigō (“I measure, weigh”). Pronunciation. (Classical ... → English: assay. Middle French: essai. French: essai; → English: essay.
  17. [17]
  18. [18]
    ASSAY Definition & Meaning - Merriam-Webster
    1. a : to analyze (something, such as an ore) for one or more specific components assayed the gold to determine its purity b : to judge the worth of : estimate
  19. [19]
    BIOASSAY Definition & Meaning - Merriam-Webster
    First Known Use. 1911, in the meaning defined above. Time Traveler. The first known use of bioassay was in 1911. See more words from the same year. Rhymes for ...
  20. [20]
    BIOASSAY Definition & Meaning - Dictionary.com
    A test used to determine such purity. Discover More. Word History and Origins. Origin of bioassay. First recorded in 1910–15; bio(logical) + assay. Discover ...
  21. [21]
    Fire Assaying History - 911Metallurgist
    Apr 29, 2017 · The beginning history of fire assaying can be traced to the finds in Troy II (about 2600 BC) and in the Cappadocian Tablets (2250-1950 BC).Missing: alchemy 2000
  22. [22]
    The History of Cupellation Test Methods - Sheffield Assay Office
    Nov 13, 2019 · The process of fire assay by cupellation is the industry standard method for determining the gold and silver content of precious metal alloys.Missing: alchemy 2000
  23. [23]
    Chromophore Formation in Resorcinarene Solutions and the Visual ...
    Resorcinol and its derivatives have long been used in simple color tests for sugars. In 1887, Seliwanoff reported a resorcinol color test which was followed by ...
  24. [24]
    Seliwanoff's Test- Definition, Principle, Procedure, Result, Uses
    Jul 24, 2013 · Seliwanoff's test is used to differentiate between sugars that have a ketone group (ketose) and sugars that have an aldehyde group (aldoses).
  25. [25]
    Rosalyn Yalow – Facts - NobelPrize.org
    Rosalyn Yalow was a nuclear physicist. She developed radioimmunoassay (RIA) together with doctor Solomon Berson. RIA is used to measure small concentrations ...
  26. [26]
    Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of ...
    Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of ... 1971 Sep;8(9):871-4. doi: 10.1016/0019-2791(71)90454-x. Authors. E Engvall, P Perlmann.Missing: development | Show results with:development
  27. [27]
    Recent progress of microfluidic chips in immunoassay - PMC - NIH
    Dec 23, 2022 · Microfluidic chip not only realizes low reagent consumption and high throughput detection, but also has obvious advantages of easy integration ...
  28. [28]
    CRISPR-based diagnostics | Nature Biomedical Engineering
    Jul 16, 2021 · We provide a rundown of the rapidly expanding toolbox for CRISPR-based diagnostics, in particular the various assays, preamplification strategies and readouts.
  29. [29]
    [PDF] Chapter 5
    To standardize an analytical method we use standards that contain known amounts of analyte. The accuracy of a standardization, therefore, depends on the quality ...
  30. [30]
    Basics of Enzymatic Assays for HTS - NCBI - NIH
    May 1, 2012 · This chapter contains basic concepts in enzyme kinetics, selection of appropriate substrates for assay design and the estimation and significance of K m and V ...Abstract · Concept · Enzyme Reaction Progress... · Measurement of Km and Vmax
  31. [31]
    limit of detection (L03540) - IUPAC Gold Book
    The value of x L is given by the equation x L = x ― b i + k s b i where x ― b i is the mean of the blank measures, s b i is the standard deviation of the blank ...Missing: assays | Show results with:assays
  32. [32]
    [PDF] Introduction - Target Discovery Institute
    REAGENTS. Reagents are a critical piece of any assay development process. This refers to all of the reagents that will be used in the assay. There are ...
  33. [33]
    Overview of Protein Assays Methods | Thermo Fisher Scientific - US
    Compatibility: Ensure that the assay kit is compatible with your sample type, such as cell lysates, tissue extracts, purified proteins, or peptides.
  34. [34]
    Basics of Assay Equipment and Instrumentation for High Throughput ...
    May 1, 2012 · This chapter contains a synopsis of general and specialized instrumentation used in screening and lead optimization laboratories.
  35. [35]
    Basics of Enzymatic Assays for HTS - NCBI - NIH
    May 1, 2012 · If Km >>> [S], then the velocity is very sensitive to changes in substrate concentrations. · Km is constant for a given enzyme and substrate, and ...Abstract · Concept · Enzyme Reaction Progress... · Measurement of Km and Vmax
  36. [36]
    Endpoint vs Kinetic Enzyme Activity Assays: When to Use Each
    May 9, 2025 · Endpoint enzyme activity assays are designed to measure the amount of product formed after the reaction has been allowed to proceed for a set period of time.
  37. [37]
    What Are Enzyme Kinetic Assays? - Tip Biosystems
    Dec 15, 2023 · An endpoint assay is an assay method that is run for a predetermined amount of time. The amount of substrate consumed and/or the quantity of ...
  38. [38]
    (PDF) Kinetic Versus Endpoint Measurement for Quantitative ...
    Aug 10, 2025 · While studying enzyme activities, two approaches can be used: (1) Two point measurements (endpoint); and (2) time-course monitoring (kinetics).
  39. [39]
    Quantifying the Interactions between Biomolecules: Guidelines for ...
    Mar 12, 2019 · Single time point assays generally assume that the change in activity is linear with time, from the start of the reaction up until the time of ...<|control11|><|separator|>
  40. [40]
    A Basic Guide to Real Time PCR in Microbial Diagnostics - Frontiers
    Feb 1, 2017 · Real time PCR (quantitative PCR, qPCR) is now a well-established method for the detection, quantification, and typing of different microbial agents.
  41. [41]
    Real-Time Polymerase Chain Reaction: Current Techniques ...
    Real-time PCR is a variation of the PCR assay to allow monitoring of the PCR progress in actual time. PCR itself is a molecular process used to enzymatically ...
  42. [42]
    Blood Glucose - Clinical Methods - NCBI Bookshelf - NIH
    In most hands, the glucose oxidase strip method is accurate and reliable. Since whole blood is used, the results tend to be slightly lower than simultaneous ...Definition · Technique · Basic Science
  43. [43]
    Multiplex Bead Array Assays: Performance Evaluation and ... - NIH
    Multiplex bead array assays provide quantitative measurement of large numbers of analytes using an automated 96-well plate format.
  44. [44]
    Cross-reactivity in antibody microarrays and multiplexed sandwich ...
    Cross-reactivity (CR) in multiplexed immunoassays has been unexpectedly difficult to mitigate, preventing scaling up of multiplexing, limiting assay performance ...
  45. [45]
    Antibody-Based Protein Multiplex Platforms - PubMed Central - NIH
    Challenges associated with multiplex configuration include selection and immobilization of capture ligands, calibration, interference between antibodies and ...
  46. [46]
    Sample Preparation and Detection Methods in Point-of-Care ... - NIH
    The process of sample preparation generally includes (1) lysis, which releases nucleic acids from cells, viruses, or other organisms, (2) extraction/ ...
  47. [47]
    Inclusion of dilution quality control samples in quantitative LC-MS ...
    Jun 6, 2024 · In LC-MS bioanalysis, sample dilution plays various roles, including bringing analyte concentrations within the validated/qualified dynamic range or ...
  48. [48]
    Comprehensive tissue homogenization and metabolite extraction for ...
    Mar 22, 2025 · This study introduces a comprehensive tissue sample preparation and metabolite quantification workflow, covering highly polar to highly lipophilic metabolites.
  49. [49]
    GC-MS Sample Preparation | Thermo Fisher Scientific - US
    Gas chromatography mass spectrometry (GC-MS) sample preparation is performed on smaller and more volatile samples including environmental pollutants, ...
  50. [50]
    Sample preparation and cleanup methods for clinical top-down ...
    The process consists of three main steps: (i) binding the analyte of interest to solid support, (ii) elimination of contaminants, and (iii) elution of target ...
  51. [51]
    Dilute and shoot approach for toxicology testing - PMC - NIH
    Dec 11, 2023 · The dilute-and-shoot method is a simple procedure used in toxicology testing, where a sample is diluted before being directly injected into the liquid ...
  52. [52]
    In vivo vs. in vitro: What is the difference? - MedicalNewsToday
    Aug 30, 2020 · In vitro is Latin for “in glass.” In vivo is Latin for “within the living.” In vitro studies often include cells in petri dishes and test tubes.
  53. [53]
    Categories of Scientific Evidence—In Vitro Data - Dietary Supplements
    In vitro experiments are also generally more rapid and less expensive to conduct than in vivo studies, thus in vitro studies are more likely than in vivo ...GENERAL TYPES OF IN... · VALIDATED IN VITRO ASSAYS · SUMMARY
  54. [54]
    A handheld plug-and-play microfluidic liquid handling automation ...
    Lab-on-a-chip technologies and microfluidics have pushed miniaturized liquid handling to unprecedented precision, integration, and automation, ...
  55. [55]
  56. [56]
    Immuno-PCR: Very Sensitive Antigen Detection by Means ... - Science
    An antigen detection system, termed immuno-polymerase chain reaction (immuno-PCR), was developed in which a specific DNA molecule is used as the marker.Missing: original | Show results with:original
  57. [57]
    Surface plasmon resonance for gas detection and biosensing
    Surface plasmon resonance for gas detection and biosensing☆. Author links open overlay panel. Bo Liedberg , Claes Nylander , Ingemar Lunström. Show more. Add ...Missing: original | Show results with:original
  58. [58]
    Nanoscale spatial dependence of avidity in an IgG1 antibody - Nature
    Jun 16, 2021 · The affinity and specificity of target recognition can increase remarkably through avidity effects, when the antibody can bind a multivalent ...
  59. [59]
    Recent Developments in Optical Detection Technologies in Lab-on ...
    Aug 21, 2014 · This review examines the recent developments in detection technologies applied to microfluidic biosensors, especially addressing several optical ...2.1. Electrochemical · 3.1. Fluorescence · 3.3. Absorbance<|separator|>
  60. [60]
    Recent Advances in Design of Fluorescence-based Assays for High ...
    All these technology advancements in fluorescence-based assays permit better portability, higher flexibility in assay design, easier operation, and enhance the ...Missing: absorbance | Show results with:absorbance
  61. [61]
    Optical biosensors: a decade in review - ScienceDirect.com
    Mar 15, 2023 · Optical biosensors have brought about an extra edge in sensing applications due to their selective, rapid and extremely sensitive measurements.Missing: absorbance | Show results with:absorbance
  62. [62]
    Point-of-care biochemical assays using electrochemical technologies
    Aug 2, 2022 · This review classifies and briefly compares commonly available electrochemical biosensors and the techniques of detection used.
  63. [63]
    Fundamentals of bio-electrochemical sensing - ScienceDirect.com
    Nov 15, 2023 · In this article, we cover the basic principles, design strategies, immobilization and regeneration techniques, along with the advantages and ...
  64. [64]
    Immunoassays and Mass Spectrometry for Determination of Protein ...
    Apr 12, 2024 · In this article, we review and compare the advantages and disadvantages of immunoassay and LC–MS/MS techniques for protein quantitation in the agriculture ...
  65. [65]
    Immunoassays and Mass Spectrometry for Determination of Protein ...
    This review contrasts the benefits and limitations of immunoassays and MS technologies for protein measurement in GM crops.
  66. [66]
    High-Throughput Droplet Digital PCR System for Absolute ...
    Oct 28, 2011 · Here we describe a high-throughput droplet digital PCR (ddPCR) system that enables processing of ∼2 million PCR reactions using conventional TaqMan assays with ...Results and Discussion · Experimental Section · Author Information · References
  67. [67]
    Mass spectrometry-based proteomics - PubMed
    Mass spectrometry-based proteomics as an indispensable tool for molecular and cellular biology and for the emerging field of systems biology.
  68. [68]
    The real-time polymerase chain reaction - PubMed
    This new technique is a refinement of the original Polymerase Chain Reaction (PCR) developed by Kary Mullis and coworkers in the mid 80:ies.
  69. [69]
    Quantitative monitoring of gene expression patterns with a ... - PubMed
    Microarrays prepared by high-speed robotic printing of complementary DNAs on glass were used for quantitative expression measurements of the corresponding genes ...
  70. [70]
    ELISA AND MULTIPLEX TECHNOLOGIES FOR CYTOKINE ... - NIH
    This article reviews ELISA and the emerging multiplex technologies, compares the cost and effectiveness of recently developed multiplex arrays with traditional ...
  71. [71]
    A Programmable Dual-RNA–Guided DNA Endonuclease ... - Science
    Jun 28, 2012 · Our study reveals a family of endonucleases that use dual-RNAs for site-specific DNA cleavage and highlights the potential to exploit the system for RNA- ...
  72. [72]
    Reconstituting organ-level lung functions on a chip - PubMed - NIH
    This bioinspired microdevice reproduces complex integrated organ-level responses to bacteria and inflammatory cytokines introduced into the alveolar space.
  73. [73]
    Rapid colorimetric assay for cellular growth and survival - PubMed
    The assay uses a tetrazolium salt to detect living cells, measuring cell activation, and can be used to measure cytotoxicity, proliferation or activation.Missing: seminal | Show results with:seminal
  74. [74]
    Trypan Blue Exclusion Test of Cell Viability - PMC - NIH
    The Trypan Blue Exclusion Test uses trypan blue to determine cell viability by observing if cells exclude the dye, with viable cells having clear cytoplasm.Missing: seminal | Show results with:seminal
  75. [75]
    A quick and simple method for the quantitation of lactate ... - PubMed
    Nov 25, 1988 · A simple way of measuring and evaluating lactate dehydrogenase release from lysed tumor cells is described.
  76. [76]
    A new generation of Ca2+ indicators with greatly improved ...
    A new family of highly fluorescent indicators has been synthesized for biochemical studies of the physiological role of cytosolic free Ca2+.Missing: imaging seminal paper
  77. [77]
    Fluorescence activated cell sorting - PubMed
    Fluorescence activated cell sorting. Rev Sci Instrum. 1972 Mar;43(3):404-9. doi: 10.1063/1.1685647. Authors. W A Bonner, H R Hulett, R G Sweet, ...Missing: invention | Show results with:invention
  78. [78]
    Comparison of the results of enzyme-linked immunosorbent assay ...
    Aug 17, 2022 · Here we assess the use of enzyme-linked immunosorbent assay (ELISA) method, a rapid, inexpensive screening method, as an alternative to more expensive methods.
  79. [79]
    Development of an ELISA for the detection of the residues ... - PubMed
    A competitive enzyme-linked immunosorbent assay (ELISA) for the chloronicotinyl insecticide imidacloprid was developed using a polyclonal antibody produced ...
  80. [80]
    Recent Advances in the Application of Bionanosensors for the ...
    This paper summarizes the aspects of electrochemical biosensors and optical biosensors for the detection of heavy metals. Basically, an electrochemical sensor ...
  81. [81]
    Biosensor for heavy metals detection in wastewater: A review
    Jul 30, 2022 · Biosensor exhibits numerous special features, such as reproducibility, reusability, linearity, sensitivity, selectivity, and stability.
  82. [82]
    Standard Methods: 5540 C: Anionic Surfactants as MBAS
    Method 5540 C measures MBAS by transferring methylene blue into an organic liquid, then measuring the blue color by spectrophotometry. MBAS are anionic ...
  83. [83]
    Continuous Flow Methylene Blue Active Substances Method ... - NIH
    This method is based on the emergence of ionic pairs, which consist of anionic surfactants and a cationic dye (methylene blue), and their transport from water ...
  84. [84]
    SW-846 Test Method 8121: Chlorinated Hydrocarbons by Gas ...
    Sep 24, 2025 · The following document discusses the method that describes the determination of chlorinated hydrocarbons in extracts prepared from environmental samples.Missing: assay | Show results with:assay
  85. [85]
    [PDF] DETERMINATION OF METHYLENE BLUE ACTIVE SUB
    The method uses liquid-liquid extraction, reacting surfactants with methylene blue, then spectrophotometric detection after back-washing with an acidified ...
  86. [86]
    Bioluminescence ATP Monitoring for the Routine Assessment of ...
    Although ATP bioluminescence technology cannot substitute traditional microbiological analyses for the determination of microbial load on food contact surfaces ...
  87. [87]
    [PDF] Use of a Newly Developed Rapid Microbial ATP bioluminescence ...
    Microbial ATP bioluminescence testing has been shown to be a rapid and accurate means of measuring Bacterial plate counts the microbial load of certain foods ...
  88. [88]
    HPLC-MS/MS in drug metabolism and pharmacokinetic screening
    This review summarizes high performance liquid chromatography coupled to a tandem mass spectrometer (HPLC-MS/MS) methodologies that are employed in drug ...
  89. [89]
    A Review of the LD50 and Its Current Role in Hazard Communication
    Dec 21, 2020 · Compounds with an oral LD50 of 0–50 mg/kg are considered highly toxic, whereas compounds with an LD50 of greater than 2000 mg/kg are considered ...History Of The Ld50 · Modern Ld Methods · Guided Example ScenarioMissing: potency | Show results with:potency
  90. [90]
    Alternative approaches in median lethality (LD50) and acute toxicity ...
    The LD50 test was introduced by Trevan in 1927 for biological standardization of dangerous drugs. Since then, the LD50 has gained wide acceptance as a ...
  91. [91]
    Development and Validation of a Plaque Assay to Determine ... - NIH
    Apr 1, 2024 · Most importantly, the plaque assay may serve as a validated method for determining vaccine titers as a basis for determining the potency of the ...
  92. [92]
    Clinical Applications of Quantitative Real-Time PCR in Virology - PMC
    Real-time PCR provides a highly valuable tool for screening, diagnosing, or monitoring diseases, as well as evaluating medical and therapeutic decision points.
  93. [93]
    High-Sensitivity Troponin: A Review on Characteristics, Assessment ...
    Mar 28, 2022 · High-sensitivity cardiac troponins are also powerful prognostic markers for long-term events and mortality, not only in a wide spectrum of other ...
  94. [94]
    Cytokines: From Clinical Significance to Quantification - PMC
    Cytokines are critical mediators that oversee and regulate immune and inflammatory responses via complex networks and serve as biomarkers for many diseases.
  95. [95]
    Single-cell analyses to tailor treatments - Science
    Sep 20, 2017 · Single-cell RNA-seq could play a key role in personalized medicine by facilitating characterization of cells, pathways, and genes associated with human ...
  96. [96]
    Single-cell transcriptomics: a novel precision medicine technique in ...
    scRNA-seq involves single-cell isolation, transcript capture, library construction, sequencing, and computational analysis, and enables evaluation of the ...
  97. [97]
    Compensate for or Minimize Matrix Effects? Strategies for ... - NIH
    Matrix effects were studied as a function of the amount of co-injected matrix extract. In spite of its potential, this method has been applied only limitedly.
  98. [98]
    Matrix Effects—A Challenge toward Automation of Molecular Analysis
    Matrix effects are complex and system specific. Each biological matrix presents different management challenges, and each type of analytical method is affected ...
  99. [99]
    Dramatic enhancement of the detection limits of bioassays via ...
    Abstract. The ability to detect biomarkers with ultrahigh sensitivity radically transformed biology and disease diagnosis.
  100. [100]
    From the bench to clinical practice: understanding the challenges ...
    Bioassays are highly variable due to the sensitivity of the cellular response to drug, changing cell viability, stage of cell cycle, cell culture media ...
  101. [101]
    Utilizing Internal Standard Responses to Assess Risk on Reporting ...
    May 15, 2015 · SIL-IS are generally used to compensate for the impact of matrix effect on the analyte instrument response in each individual sample (23–25).
  102. [102]
    Enzyme-Linked Immunosorbent Assay (ELISA) and Blocking ... - NIH
    To eliminate the residual binding capacity of the wells, blocking agents such as bovine serum albumin (BSA), non-fat dry milk, and whole serum are commonly used ...
  103. [103]
    Electrochemistry-based Approaches to Low Cost, High Sensitivity ...
    The major challenges include automation and meeting the immunoassay requirements for sensitive and specific cancer diagnostics. ... solutions. We made NP ...
  104. [104]
    Automated high-throughput microchannel assays for cell biology
    Cell seeding consistency between each microchannel and within each microchannel was found to be within a standard deviation of less than 5% and 6% respectively.Materials And Methods · Liquid Handling · Robustness And Cell Seeding...
  105. [105]
    SEAOP: a statistical ensemble approach for outlier detection in ...
    Mar 31, 2024 · SEAOP is a Python toolbox for outlier detection in proteomics using multi-round resampling, multiple models, and a chi-square test for ...
  106. [106]
    Anomaly detection for high-content image-based phenotypic cell ...
    Oct 29, 2025 · High-content image-based phenotypic profiling combines automated microscopy and analysis to identify phenotypic alterations in cell ...Missing: post- | Show results with:post-
  107. [107]
    Antibody Colocalization Microarray: A Scalable Technology for ... - NIH
    Cross-reactivity, arising because detection antibodies are mixed, is a known weakness of multiplex sandwich assays that is mitigated by lengthy optimization.
  108. [108]
    BioAssays - PubChem - NIH
    PubChem BioAssay contains small-molecule and RNAi screening data along with associated annotation information from contributing organizations.
  109. [109]
    ChEMBL - EMBL-EBI
    ChEMBL is a manually curated database of bioactive molecules with drug-like properties. It brings together chemical, bioactivity and genomic dataDatabase Schema · 2496335 Distinct Compounds · 16003 Targets
  110. [110]
    ChEMBL 36 is live | EMBL-EBI
    Oct 15, 2025 · The new ChEMBL 36 release is now live. ChEMBL is a manually curated database of bioactive molecules with drug-like properties.
  111. [111]
    ChEMBL Database in 2023: a drug discovery platform spanning ...
    Nov 2, 2023 · The core content of the ChEMBL database is published bioactivity data, from a set of seven Medicinal Chemistry journals: Journal of Medicinal ...
  112. [112]
    Binding Database Home
    The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.Binding Database Home · Pathway in Binding Database · Download · Name
  113. [113]
    a FAIR knowledgebase of protein-small molecule binding data
    BindingDB (bindingdb.org) is a public, web-accessible database of experimentally measured binding affinities between small molecules and proteins.
  114. [114]
    Info - BindingDB
    BindingDB is a public, web-accessible database of measured binding affinities, focusing chiefly on the interactions of proteins considered to be candidate drug ...
  115. [115]
    Inferring molecular inhibition potency with AlphaFold predicted ...
    Apr 8, 2024 · This study presents a proteo-chemometric drug screening approach that uses a simple and scalable method for extracting protein structural information.<|separator|>
  116. [116]
    Exploiting PubChem and other public databases for virtual ...
    This review provides an overview of recent (2024–2025) trends in mining data from PubChem and other representative public databases for virtual screening.
  117. [117]
    About protocols.io
    protocols.io is perfect for science methods, assays, clinical trials, operational procedures and checklists for keeping your protocols up to date as recommended ...Missing: launch | Show results with:launch
  118. [118]
    A conversation with Lenny Teytelman, co-founder and CEO of ...
    Dec 15, 2020 · Lenny Teytelman, Irina Makkaveeva, and Alexei Stoliartchouk launched protocols.io in 2014. Lenny has over a decade of computational and ...
  119. [119]
    Springer Nature continues open research drive with acquisition of ...
    Jul 26, 2023 · Springer Nature, the world's leading publisher of protocols, has acquired protocols.io - a secure platform for developing and sharing reproducible methods.
  120. [120]
    Countway's protocols.io Pilot Extended for Three Years
    Apr 1, 2024 · Today, we are happy to announce an extension through January 30, 2027. Over the last four years, we have seen exponential growth in users (179%) ...Missing: expansion | Show results with:expansion
  121. [121]
    Assay Guidance Manual - NCBI Bookshelf - NIH
    The Assay Guidance Manual is a resource for optimizing assays to evaluate molecules for developing probes, covering HTS, SAR, and assay formats.
  122. [122]
    Assay Guidance Manual: Quantitative Biology and Pharmacology in ...
    The Assay Guidance Manual (AGM) is an eBook of best practices for the design, development, and implementation of robust assays for early drug discovery.
  123. [123]
    MIAPE - HUPO Proteomics Standards Initiative
    MIAPE is reporting guidelines for proteomics, defining the minimum information about a proteomics experiment. It is registered with MIBBI.Missing: assays | Show results with:assays<|separator|>
  124. [124]
    The minimum information about a proteomics experiment (MIAPE)
    This paper describes the processes and principles underpinning the development of these modules; discusses the ramifications for various interest groups.Missing: assays | Show results with:assays
  125. [125]
    The minimum information about a proteomics experiment (MIAPE)
    Aug 8, 2007 · The MIAPE guidelines should require sufficient information about a dataset and its experimental context to allow a reader to understand and ...Missing: assays | Show results with:assays
  126. [126]
    AI Tools for Protocol Optimization
    Explore AI-powered tools that support protocol design, optimization, and troubleshooting—helping researchers improve experimental workflows, save time, and ...Missing: Guidance Manual post- 2022